Trial Profile
Identification of potential predictors and surrogates for the selection of patients who may benefit from the use of Racotumomab, as switch maintenance therapy, in patients with non-small cell lung cancer, stages IIIA, IIIB and IV.
Status:
Not yet recruiting
Phase of Trial:
Phase 0
Latest Information Update: 14 Oct 2020
Price :
$35
*
At a glance
- Drugs Racotumomab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 14 Nov 2018 New trial record